Incretin Receptors for Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Are Essential for the Sustained Metabolic Actions of Vildagliptin in Mice | Zendy

Grace Flock | Zendy; Laurie L. Baggio | Zendy; Christine Longuet | Zendy; Daniel J. Drucker | Zendy

Open Access

Incretin Receptors for Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Are Essential for the Sustained Metabolic Actions of Vildagliptin in Mice

Author(s) -

Grace Flock,

Laurie L. Baggio,

Christine Longuet,

Daniel J. Drucker

Publication year - 2007

Publication title -

diabetes

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.219

H-Index - 330

eISSN - 1939-327X

pISSN - 0012-1797

DOI - 10.2337/db07-0697

Subject(s) - vildagliptin , incretin , glucagon like peptide 1 , medicine , receptor , endocrinology , glucagon , chemistry , diabetes mellitus , insulin , type 2 diabetes

Dipeptidyl peptidase-4 (DPP4) inhibitors lower blood glucose in diabetic subjects; however, the mechanism of action through which these agents improve glucose homeostasis remains incompletely understood. Although glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP) represent important targets for DPP4 activity, whether additional substrates are important for the glucose-lowering actions of DPP4 inhibitors remains uncertain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research